Zai Lab
Emily Fan currently serves as the Director of Program & Portfolio Management at Zai Lab since October 2022. Prior to this role, Emily held multiple positions at Bristol Myers Squibb, including Associate Director and Senior Manager in R&D Strategy and Planning from April 2018 to October 2022. Between August 2016 and April 2018, Emily was the Senior Manager of Strategic Project Management at Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and briefly worked as a Country Study Manager at Roche in 2016. Emily's earlier career at Bayer Pharmaceuticals spanned nearly seven years, during which various roles included Clinical Research Associate and CLM. Emily started in the industry as a Senior Clinical Research Associate at Excel PharmaStudies Inc. from June 2008 to July 2009. In the academic sphere, Emily has extensive qualifications, holding an MBA in Finance from Webster University and a Master's degree in Finance from Shanghai University of Finance and Economics, alongside a Bachelor's degree in Chinese Medicine from Chengdu University of Traditional Chinese Medicine.
This person is not in any teams
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.